Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0002903,
umls-concept:C0015131,
umls-concept:C0022614,
umls-concept:C0143993,
umls-concept:C0150369,
umls-concept:C0871261,
umls-concept:C1444748,
umls-concept:C1513492,
umls-concept:C1524063,
umls-concept:C1704632,
umls-concept:C1705994,
umls-concept:C1706817,
umls-concept:C2348609,
umls-concept:C2911692
|
pubmed:issue |
3
|
pubmed:dateCreated |
1997-9-26
|
pubmed:abstractText |
Intraoperative monitoring of myogenic transcranial motor evoked responses (tc-MERs) requires an anesthetic technique that minimally depresses response amplitudes. Acceptable results have been obtained during opioid/N2O anesthesia, provided that the concentration of N2O does not exceed 50%. However, this technique may necessitate supplementation with additional agents to achieve adequate depth of anesthesia. Etomidate and ketamine have been reported anecdotally or in nonsurgical situations to produce little tc-MER depression. We investigated the effects on tc-MER amplitude and latency of supplementation of a sufentanil/N2O anesthetic with etomidate or ketamine in patients undergoing spinal instrumentation. Anesthesia was induced with etomidate 0.3 mg/kg and sufentanil 1.5 mg/kg and maintained with sufentanil 0.5 mg/kg/h and N2O 50%. Muscle relaxation was kept at 25% of control. Paired transcranial electrical stimulation was performed. Each patient randomly received either ketamine (0.5 mg/kg) or etomidate (0.1 mg/kg) as a single bolus intravenously, during stable surgical conditions. Triplicate tc-MERs were recorded from the tibialis anterior muscles before and 2, 5, 10, and 15 min after drug administration. Administration of ketamine did not significantly change tc-MER amplitudes, whereas etomidate resulted in a transient amplitude depression to 72% of control (p < 0.05) at 2 min after injection. Latency remained unchanged with both drugs. In conclusion, the data suggest that both ketamine (0.5 mg/kg) and etomidate (0.1 mg/kg) can be used to supplement sufentanil/N2O anesthetic without disrupting tc-MER monitoring.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anesthetics, General,
http://linkedlifedata.com/resource/pubmed/chemical/Anesthetics, Intravenous,
http://linkedlifedata.com/resource/pubmed/chemical/Etomidate,
http://linkedlifedata.com/resource/pubmed/chemical/Ketamine,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrous Oxide,
http://linkedlifedata.com/resource/pubmed/chemical/Sufentanil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0898-4921
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
228-33
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9239584-Adolescent,
pubmed-meshheading:9239584-Adult,
pubmed-meshheading:9239584-Anesthesia, General,
pubmed-meshheading:9239584-Anesthesia, Intravenous,
pubmed-meshheading:9239584-Anesthetics, General,
pubmed-meshheading:9239584-Anesthetics, Intravenous,
pubmed-meshheading:9239584-Child,
pubmed-meshheading:9239584-Electric Stimulation,
pubmed-meshheading:9239584-Etomidate,
pubmed-meshheading:9239584-Evoked Potentials,
pubmed-meshheading:9239584-Female,
pubmed-meshheading:9239584-Humans,
pubmed-meshheading:9239584-Ketamine,
pubmed-meshheading:9239584-Male,
pubmed-meshheading:9239584-Middle Aged,
pubmed-meshheading:9239584-Motor Cortex,
pubmed-meshheading:9239584-Muscle, Skeletal,
pubmed-meshheading:9239584-Nitrous Oxide,
pubmed-meshheading:9239584-Sufentanil
|
pubmed:year |
1997
|
pubmed:articleTitle |
The use of ketamine or etomidate to supplement sufentanil/N2O anesthesia does not disrupt monitoring of myogenic transcranial motor evoked responses.
|
pubmed:affiliation |
Department of Anesthesiology, University of Amsterdam, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|